Linneo Health Expands Medicinal Cannabis Offering With Industrial Cannabis Derivatives

Linneo Health has expanded its medicinal cannabis offering to include industrial derivatives. This follows the issuance of good manufacturing practice (EU-GMP) certification for the industrial processing of cannabis derivatives to Alcaliber, by the Spanish Agency of Medicines and Medical Products.

Under the terms of an exclusive CDMO agreement with Alcaliber, Linneo Health now adds the capabilities to supply APIs and medicinal finished dosage forms, such as THC and standardized cannabis extracts, in addition to its existing EU-GMP certified medicinal cannabis flowers.

Don Bellamy, CEO of Linneo Health, stated: “Our ability to supply industrial derivatives to the highest quality, in addition to our existing expertise in the cultivation and delivery of cannabis flowers to our partners, marks a major expansion in our portfolio and further cements our position as a global leader in the field. As the medicinal cannabis market evolves globally, alongside a changing landscape of regulatory and legal reforms, Linneo Health is primed to maintain its leadership position with a broad portfolio offering and a complete service to our customers.”

José Antonio de la Puente, CEO of Alcaliber, stated: “Adding full cannabis industrial derivatives, from APIs to standardized extracts, is a great milestone for our company. Bringing our experience of more than 90 years in extraction of active substances from herbal plants is a differential asset in the complex pharmaceutical cannabis industry. Our commitment to the highest standards of quality and innovation, combined with our focus on continuous improvement, underpins our new family of products.”

Photo by Richard T on Unsplash

Related News

Cannabis Movers & Shakers: Leafly Holdings, Linneo Health, Flowhub, MindMed